ILMN (ILMN) Stock Analysis

ILMN (ILMN) is a publicly traded company in the HEALTHCARE sector. It trades at $162.55, carries a market capitalization of $24.87B, a price-to-earnings ratio of 29.84. This page summarizes the public market data, fundamentals, and frequently asked questions for ILMN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DIAGNOSTICS & RESEARCH

Exchange: NASDAQ

Key Metrics

• Price: $162.55
• Market Cap: $24.87B
• P/E Ratio: 29.84
• EPS: $5.51
• 52-Week High: $165.97
• 52-Week Low: $81.76

Market Sentiment

ILMN currently has a Bullish sentiment score of 0.23.

About ILMN

Illumina, Inc. is a prominent global leader in the biotechnology sector, headquartered in San Diego, California, and established in 1998. The company is renowned for its cutting-edge technologies and integrated systems for genomic analysis, with a strong focus on sequencing, genotyping, and gene expression solutions. Illumina's diverse product offerings cater to various markets, including research, clinical diagnostics, and agricultural genomics, significantly advancing the field of personali...

GNG Research Analysis

GNG Research scores ILMN (ILMN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ILMN.

Frequently Asked Questions

Does ILMN pay dividends?

ILMN (ILMN) does not currently pay a regular dividend.

What is ILMN's P/E ratio?

ILMN has a price-to-earnings (P/E) ratio of 29.84.

What is ILMN's market cap?

ILMN (ILMN) has a market capitalization of $24.87B with a current stock price of $162.55.